IO Biotech appoints Qasim Ahmad as CMO, promotes Eric Faulkner to CTO

IO Biotech, Inc.

Qasim Ahmad, MD, appointed CMO effective July 15; previously Novartis SVP, US Head Clinical Development & Medical Affairs.
Eva Ehrnrooth transitions from CMO to Senior Clinical Advisor; departure not due to any disagreement.
Eric Faulkner promoted to CTO; previously Sr. VP CMC, will oversee CMC and Quality for commercial readiness.
Ahmad granted inducement option for 288,153 shares vesting over 4 years (25% cliff at year one).
Changes position company for BLA filing and next stage of growth; Ahmad based in US.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Qasim Ahmad

Chief Medical Officer

IOBTQ · IO Biotech, Inc.

Effective: 2023-07-15
Filed: July 18, 2023, 7:59 PM ET

On July 15, 2023, IO Biotech, Inc. (the “Company”) appointed Qasim Ahmad, M.D. as the Company’s Chief Medical Officer, effective as of that same date.

Role change

Eva Ehrnrooth

Senior Clinical Advisor

IOBTQ · IO Biotech, Inc.

Successor: Qasim Ahmad
Filed: July 18, 2023, 7:59 PM ET

Dr. Ehrnrooth will now transition from her role as Chief Medical Officer to Senior Clinical Advisor, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Qasim Ahmad was appointed as Chief Medical Officer at IO Biotech, Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

On July 15, 2023, IO Biotech, Inc. (the “Company”) appointed Qasim Ahmad, M.D. as the Company’s Chief Medical Officer, effective as of that same date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Eva Ehrnrooth changed role as Senior Clinical Advisor at IO Biotech, Inc..

Action: transition
Role: Senior Clinical Advisor

Exact text from the filing

Dr. Ehrnrooth will now transition from her role as Chief Medical Officer to Senior Clinical Advisor, effective immediately.

View on SEC.gov

IO Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-188851

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.